- General info
- Available languages
- Background story
Supports up to 50 languages.
Please select a format to view the available languages:
Supports up to 11 OpenType features.
Please select a format to view the available OpenType features:
Diverda Sans is a geometric family of typefaces that are all free from ornament. Swiss designer Daniel Lanz optimized Diverda Sans for maximum legibility. In contrast to many other modern typefaces, which try to squeeze the traditional rounder forms of the alphabet into square designs, and which often attempt to equalize the widths of the capital letters, Diverda Sans remains true to the proper proportions of the Roman alphabet. The x-heights of Diverda's characters are low, and the differences between curved, square, and triangular elements are very clear. Like the more calligraphic typefaces of the past, Diverda's strokes exhibit contrast that is inspired by movements of the pen on paper; down strokes are heavier than up strokes. Possible applications for the Diverda Sans include magazine design, as well as advertising for fashion, design, or architectural products. Because of its 10 different individual styles or weights, Diverda Sans is also a good fit for Corporate Identity solutions.
Diverda Sans has a matching serif companion family,
The ten fonts in the Diverda Sans family are all Linotype Com" OpenType fonts; their character set includes glyphs necessary for the setting of 48 Latin-based languages. These include all of the languages in Western, Central, and Eastern Europe that use the Roman alphabet (including the Baltics and Turkey). Also, the upright fonts in the Diverda Sans family include extra ligatures, small caps, small cap figures, and oldstyle figures. The Italic fonts include extra ligatures and oldstyle figures."
Download a free trial
Use this font in your own documents with a free 5 minute trial through SkyFonts. Trials are for evaluation purposes only. Learn more.
This font is currently not available.
You already tried this font within the last 24 hours or you may have exceeded your daily allowance of trials. Learn more.